Cancer reports最新文献

{"title":"The Prognostic Role of Vimentin Expression in Triple-Negative Breast Cancer: A Retrospective Cohort Study","authors":"Erwin Danil Yulian,&nbsp;Tantri Hellyanti,&nbsp;Karl Heinz Leonhardt Rowika","doi":"10.1002/cnr2.70632","DOIUrl":"10.1002/cnr2.70632","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Triple-negative breast cancer (TNBC) is a subtype of breast cancer with the poorest prognosis and aggressive biological behavior. In Indonesia, approximately 15%–25% of breast cancer cases fall into the TNBC category. One of the biological markers involved in the epithelial–mesenchymal transition (EMT) process and tumor progression of TNBC is vimentin. Positive vimentin expression has been reported to correlate with reduced survival; however, data in the Indonesian population remain limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included 29 TNBC patients who received treatment at Dr. Cipto Mangunkusumo National General Hospital between 2017 and 2022, with a 3-year follow-up period. Clinicopathological data and vimentin expression were analyzed using bivariate analysis and Kaplan–Meier survival analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most patients were aged ≥ 40 years (82.8%), had a normal body mass index (82.8%), presented with locally advanced disease (72.4%), high histopathological grade (62.1%), and high Ki-67 expression (72.4%). A significant association was observed between vimentin expression and overall survival (<i>p</i> = 0.019), where increased vimentin expression was associated with reduced survival (mean survival 30.42 months in the negative group vs. 20.86 months in the positive group). Vimentin expression was also significantly associated with Ki-67 expression (<i>p</i> = 0.045), indicating a link between cellular proliferation and activation of EMT. Further analysis in patients with TNBC demonstrated that positive vimentin expression significantly increased the risk of mortality (<i>p</i> = 0.015; HR 5.64; 95% CI 1.39–22.7), while inadequate treatment was also associated with poorer overall survival (<i>p</i> = 0.011; HR 4.05; 95% CI 1.37–11.9).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vimentin expression is significantly associated with reduced overall survival in patients with TNBC and correlates with high Ki-67 expression, reflecting tumor aggressiveness and activation of EMT. Inadequate treatment also contributes to poorer survival outcomes. These findings highlight the potential role of vimentin as a prognostic molecular marker in TNBC within the Indonesian population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13659795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral Lymphocyte Subsets Predict Efficacy and Overall Survival in Gastric Cancer Patients Receiving Preoperative Chemotherapy: A Retrospective Cohort Study","authors":"Zirui Xue,&nbsp;Dan Liu,&nbsp;Zhaodong Sun,&nbsp;Bosen Li,&nbsp;Xinyou Liu,&nbsp;Junjie Zhao,&nbsp;Haojie Li,&nbsp;Xuefei Wang,&nbsp;Zhaoming Wang","doi":"10.1002/cnr2.70704","DOIUrl":"10.1002/cnr2.70704","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pathologic complete response (pCR), which reflects the local immune status and preoperative chemotherapy efficacy, has garnered significant attention in gastric cancer research. However, the predictive value of peripheral lymphocyte subsets for pCR in gastric cancer patients receiving preoperative chemotherapy remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aims to assess the correlation between preoperative peripheral lymphocyte subsets and pCR in gastric cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>In this retrospective study, gastric cancer patients who underwent curative gastrectomy following preoperative chemotherapy were included. Cytokines and peripheral lymphocytes were measured using flow cytometry. Clinicopathological characteristics, peripheral lymphocyte data and cytokine data were collected for the analysis. Overall survival (OS) was analyzed using Kaplan–Meier curves. Of 173 patients, 15 (8.7%) achieved pCR. A lower proportion of CD19⁺ B cells (7.5% vs. 10.4%, <i>p</i> = 0.008) was associated with pCR, and a high absolute count of NK cells was associated with better OS (<i>p</i> = 0.044).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study indicated that a lower proportion of CD19⁺ B cells may serve as a predictive biomarker for pCR, while an increased peripheral NK cell count could function as an auxiliary factor for risk stratification when combined with clinical parameters to assess long-term outcomes in gastric cancer patients receiving preoperative chemotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13659800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and Caregiver Reported Barriers to Cancer Clinical Trial Participation: A Scoping Review","authors":"Sarah Scruton,&nbsp;Chisato Ito,&nbsp;Julia Bohnen,&nbsp;Robin Urquhart,&nbsp;Chiquita Hessels,&nbsp;Summer Konechny,&nbsp;Rosilene Kraft,&nbsp;Randy Thompson,&nbsp;Cheryl Ho,&nbsp;Deirdre Weymann,&nbsp;Yvonne Bombard,&nbsp;Emanuel Krebs,&nbsp;Avram Denburg,&nbsp;Timothy P. Hanna,&nbsp;Howard J. Lim,&nbsp;Saadia Shareen,&nbsp;Dean A. Regier,&nbsp;Samantha Pollard","doi":"10.1002/cnr2.70700","DOIUrl":"10.1002/cnr2.70700","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The development of cancer treatments relies on patient participation in clinical trials, yet poor recruitment and retention hinder evidence generation. There exists an urgent need for trial designs that address patient-identified barriers, informational gaps, and concerns. The goal of this evidence synthesis was to identify patient- and caregiver-reported barriers to trial participation and retention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a search in PubMed, Ovid MEDLINE, CINAHL Complete, Scopus, and Web of Science to identify studies describing patient- and caregiver-reported barriers to cancer clinical trial participation. Eligible studies included qualitative or quantitative research published in the English language that reported barriers experienced by individuals with cancer or their caregivers. Four authors screened titles and abstracts, followed by full-text review and data abstraction of included studies. Qualitative results were summarized narratively, and quantitative findings were described using descriptive statistics. Barriers and recommendations for improved clinical trial design were categorized into thematic groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The search yielded 7918 studies, with 131 meeting inclusion criteria. Barriers to trial participation were grouped into three overarching themes: (1) psychosocial barriers (e.g., fear of adverse events, distrust, and perceived limited personal benefit); (2) logistical barriers (e.g., travel requirements and financial burden); and (3) informational barriers (e.g., challenges understanding consent materials). Recommendations emphasized financial and logistical support for participants, appropriate information provision, and fostering trust between patients and trial staff.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Addressing informational, psychosocial, and logistical obstacles to participation is essential for timely evidence generation. Without meaningful strategies to engage patients and caregivers in clinical trial designs, evidence generation for novel oncology innovations will continue to lag, hampering patient access and appropriate reimbursement.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Analysis of Circulating miR-486-3p and miR-21-5p in Early Detection and Subtype Classification of Luminal A and B Breast Cancer in Peruvian Women","authors":"Desireé Bouroncle,&nbsp;Gustavo Colque,&nbsp;Luis Huaytalla-Bautista,&nbsp;María Claudia Flores-Berrospi,&nbsp;Carla Bernal,&nbsp;Ivan Belzusarri,&nbsp;Jorge Dunstan,&nbsp;Mónica Paredes-Anaya","doi":"10.1002/cnr2.70717","DOIUrl":"https://doi.org/10.1002/cnr2.70717","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer (BC) remains the most common malignancy among women worldwide, and early detection is essential for improving clinical outcomes. There is a growing need for accessible, minimally invasive molecular biomarkers that complement current diagnostic approaches and support molecular subtype classification.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This exploratory case–control study evaluated the plasma expression of four circulating miRNAs (miR-21-5p, miR-486-3p, miR-451a, and miR-660-5p) in Peruvian women with Luminal A (<i>n</i> = 32) and Luminal B (<i>n</i> = 43) breast cancer and healthy controls (<i>n</i> = 36).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Expression levels were quantified by qPCR, and diagnostic performance was assessed using logistic regression with leave-one-out cross-validation (LOOCV). miR-486-3p was significantly upregulated in Luminal A compared with both controls and Luminal B, whereas miR-21-5p was downregulated relative to controls. After validation, miR-486-3p retained moderate discriminative ability for distinguishing Luminal A from controls (AUC = 0.651; 95% CI: 0.461–0.841; <i>p</i> = 0.120), while the combined miR-486-3p/miR-21-5p model showed moderate discriminatory performance for differentiating Luminal A from Luminal B (AUC = 0.690; 95% CI: 0.466–0.914; <i>p</i> = 0.0959). Exploratory functional enrichment analyses suggested that experimentally validated targets of these miRNAs were associated with cancer- and immune-related pathways, providing biological context for their potential roles in breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings provide preliminary evidence supporting the potential of circulating miR-486-3p and miR-21-5p as candidate non-invasive biomarkers for future early detection and molecular subtype classification of Luminal breast cancer. However, these findings should be interpreted cautiously and require validation in larger, independent cohorts before clinical implementation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70717","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myelodysplastic Syndromes-Transformed Acute Myeloid Leukemia With Concurrent DEK::CAN Fusion Gene Positivity and WT1 Overexpression: A Case Report and Literature Review","authors":"Wanxiu Mao,&nbsp;Tengmin Zhou,&nbsp;Xi Xu,&nbsp;Sheng Luo,&nbsp;Songfu Jiang,&nbsp;Zhijie Yu","doi":"10.1002/cnr2.70714","DOIUrl":"10.1002/cnr2.70714","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders with a risk of progression to acute myeloid leukemia (AML). MDS-transformed AML (MDS-AML) has a poor prognosis. The concurrent presence of DEK::CAN fusion gene positivity and WT1 overexpression is extremely rare and likely denotes a highly aggressive disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 57-year-old Han Chinese female with a 5-year history of MDS (DEK::CAN status at initial diagnosis unknown) presented with fatigue and pancytopenia. Bone marrow blasts accounted for 81% (AML-M5), and karyotype showed t(6;9)(p23;q34). Real-time quantitative PCR (qPCR) revealed a DEK::CAN/ABL ratio of 188.21% and a WT1/ABL ratio of 52.90%; next-generation sequencing identified a U2AF1 mutation (p.Arg156His). The patient received IA regimen induction followed by intermediate-dose cytarabine consolidation. Complete remission (CR) was achieved after induction; after the first consolidation cycle, a transient CR with incomplete hematologic recovery (CRi) occurred, and CR was re-established at the final evaluation. Severe infections occurred repeatedly during treatment. Although the patient achieved CR after induction chemotherapy, recurrent infections and cumulative chemotherapy-related cytopenias prevented timely allogeneic hematopoietic stem cell transplantation (allo-HSCT). She died approximately 1 month after the last chemotherapy cycle; the cause was clinically suspected to be fatal hemorrhage, though autopsy was not performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MDS-AML with concurrent DEK::CAN and WT1 mRNA overexpression is a highly aggressive entity. Although chemotherapy can induce remission, treatment-related complications often preclude transplantation. Early molecular screening is recommended, and once any form of remission (CR or CRi) is achieved, prompt bridging to allo-HSCT should be pursued. Targeted therapy should also be explored.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70714","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of COL6A1 in Tumor Matrix of Cholangiocarcinoma and Its Mechanism of Tumor Progression","authors":"Weibin Zhang,&nbsp;Chongshi Gao,&nbsp;Chongzhou Lan,&nbsp;Jia Dong,&nbsp;Boxing Xu,&nbsp;Yingmei Li,&nbsp;Jin Dai,&nbsp;Baitong Che,&nbsp;Cheng Li,&nbsp;Gang Dong,&nbsp;Yunfei Wu,&nbsp;Bo Li,&nbsp;Cheng Yang,&nbsp;Lingmei Kong","doi":"10.1002/cnr2.70716","DOIUrl":"10.1002/cnr2.70716","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cholangiocarcinoma (CCA), a malignant tumor originating from the bile duct epithelial cells, is characterized by aggressive invasion and poor prognosis. Abnormal remodeling of the tumor microenvironment plays a pivotal role in its disease progression. The tumor stroma, which is a core component of the tumor microenvironment, comprises an extracellular matrix and various stromal cells. Changes in its composition are closely associated with tumor proliferation, invasion, metastasis, and drug resistance. Collagen Type VI alpha 1 chain (COL6A1), an important functional protein in the extracellular matrix, plays a carcinogenic role in multiple malignant tumors; it participates in matrix remodeling and cellular signaling and influences the tumor immune microenvironment. This systematic review aims to examine the biological properties of COL6A1 and the structural characteristics of CCA tumor stroma, and summarize the roles of stromal COL6A1 in CCA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>We outline the expression patterns of stromal COL6A1 in CCA and its correlation with clinicopathological features. Specifically, we systematically discuss the molecular mechanisms by which COL6A1 facilitates CCA progression, including mediating stromal remodeling, cancer-associated fibroblast activation, oncogenic signaling cascades, the immunosuppressive microenvironment, and therapeutic resistance. COL6A1 shows translational potential as a diagnostic biomarker, staging indicator, and prognostic predictor for CCA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>COL6A1 is a critical molecule regulating stromal remodeling and malignant progression of CCA. This review highlights the current research gaps and proposes prospective research directions, providing a theoretical foundation for future investigations and clinical translations using COL6A1 in CCA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70716","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Gastric Cancer: Diagnostic, Prognostic, and Predictive Developments, Evidence Maturity, and Translational Challenges","authors":"Chong Chen,&nbsp;Weisong Xu,&nbsp;Tong Wu,&nbsp;Junpeng Zhao,&nbsp;Xuebing Xu,&nbsp;Mingbing Xiao,&nbsp;Kang Xu","doi":"10.1002/cnr2.70665","DOIUrl":"10.1002/cnr2.70665","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gastric cancer (GC) remains a major global health burden characterized by substantial heterogeneity in diagnosis, prognosis, and treatment response. Artificial intelligence (AI), including machine learning (ML) and deep learning (DL), has been increasingly investigated for the analysis of endoscopic images, radiological scans, whole-slide pathology images, molecular profiles, liquid-biopsy data, and multimodal clinical datasets. This structured review summarizes recent AI-based developments in GC diagnosis, staging, prognostic assessment, and treatment-response prediction, with particular emphasis on the translational maturity of the available evidence. PubMed/MEDLINE, Web of Science, Embase, Scopus, and Google Scholar were searched for relevant English-language publications from database inception through January 2026. Eligible studies were evaluated according to clinical task, data modality, model type, cohort size, study design, validation strategy, interpretability, clinical workflow readiness, and reported limitations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>Recent AI models have demonstrated promising performance in selected research settings, particularly in endoscopic image analysis, computational pathology, CT-based radiomics, and multimodal prognostic modeling. However, most studies remain retrospective, single-center, and internally validated. Calibration, robustness, prospective clinical utility, and generalizability across populations and institutions remain insufficiently assessed. Major barriers to translation include data heterogeneity, annotation variability, overfitting, data leakage, external validation failure, algorithmic bias, regulatory requirements, reimbursement, clinician-AI interaction, medicolegal responsibility, post-deployment monitoring, and model drift.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>AI has considerable potential to support GC diagnosis, prognosis, and treatment planning, but most current models remain insufficiently validated for routine clinical use. Future progress will depend on transparent reporting, standardized validation, multicenter prospective trials, clinically meaningful endpoints, and the integration of explainable, trustworthy AI systems into routine clinical workflows.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70665","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DKK1 Promotes Cisplatin Resistance in Oral Squamous Cell Carcinoma via SLC3A2-Dependent Ferroptosis Suppression","authors":"Zhuoxuan Liu,&nbsp;Xiaolan Chen,&nbsp;Yucong Lin,&nbsp;Lijun Zhu","doi":"10.1002/cnr2.70715","DOIUrl":"10.1002/cnr2.70715","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Oral squamous cell carcinoma (OSCC) is a prevalent malignancy associated with poor outcomes, largely attributable to cisplatin resistance—the standard chemotherapeutic agent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>While ferroptosis has been proposed as a promising therapeutic target, how it is regulated in OSCC remains largely unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>To determine DKK1 expression levels and their prognostic implication, the TCGA-HNSC cohort and OSCC patient samples were examined. The impact of DKK1 silencing and/or cisplatin treatment on cell proliferation and ferroptosis-related markers, including reactive oxygen species (ROS), malondialdehyde (MDA), and glutathione (GSH) levels, was investigated in vitro. Additionally, the efficacy of DKK1 inhibition was evaluated in xenograft models. The findings revealed that DKK1 expression was markedly elevated in the TCGA-HNSC cohort and was further validated in OSCC tissues. High DKK1 expression was associated with worse survival and contributed to cisplatin resistance, while DKK1 silencing sensitized cells to ferroptosis and enhanced cisplatin cytotoxicity. Mechanistically, our data support a regulatory model in which DKK1 maintains SLC3A2 expression through modulation of the β-catenin/STAT3 axis, thereby contributing to ferroptosis suppression and cisplatin resistance. In vivo, DKK1 inhibition improved cisplatin efficacy, at least in part, by promoting SLC3A2-associated ferroptosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings support DKK1 as a potential regulator of ferroptosis and cisplatin resistance in OSCC. Targeting the DKK1/SLC3A2 axis to restore ferroptotic sensitivity may represent a promising strategy to overcome chemoresistance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70715","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Patient-Reported Outcomes and Dosimetric Predictors of Quality of Life After Curative-Intent Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: A Cross-Sectional Study","authors":"Anna Lawless,&nbsp;Dasantha Jayamanne,&nbsp;Lisa Parker,&nbsp;Esther Duruchukwu,&nbsp;Paula Macleod,&nbsp;Venkatesha Venkatesha,&nbsp;Christopher Brown,&nbsp;Alexander Guminski,&nbsp;Adrian Lee,&nbsp;Michael Back,&nbsp;Thomas Eade,&nbsp;Sarah Bergamin","doi":"10.1002/cnr2.70712","DOIUrl":"10.1002/cnr2.70712","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Radiation therapy (RT) is central to curative treatment for oropharyngeal squamous cell carcinoma (OPSCC) but may cause late side effects that can adversely impact quality of life (QOL). As OPSCC treatment becomes more personalised, clinically meaningful QOL endpoints and their predictors are increasingly important.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To assess long-term QOL, treatment regret, and predictors of QOL after curative-intent RT for OPSCC.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods and Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This cross-sectional survey included patients with primary OPSCC treated with curative intent RT between 2007 and 2023 at a single tertiary institution. Patients completed validated EORTC QOL questionnaires and additional items assessing perceived health and treatment regret. Survival outcomes were estimated using Kaplan–Meier methods, and compared by p16 status using log-rank test. QOL scores were analysed as continuous variables using univariate and multivariable linear regression models, with prespecified dosimetric predictors tested against clinically corresponding EORTC QOL-HN43 symptom scales and adjusted for multiple comparisons. Of the 344 patients treated, 274 (80%) had p16-positive disease. At median follow of 7.7 years, 5-year overall survival was 90% for p16-positive versus 52% for p16-negative disease, and disease-free survival 89% versus 72%. Of 232 patients contacted, 186 (80%) completed the QOL survey at median 6.3 years after RT. 173 (93%) reported no treatment regret regarding RT. Mean global health status was 81.3/100, while dry mouth/sticky saliva was the most affected domain (mean 41.9/100). On multivariable analysis, older age was associated with worse global health status (−4.9 points per 10 years, &lt;i&gt;p&lt;/i&gt; = 0.001) and higher contralateral mean parotoid dose with worse dry mouth/sticky saliva scores (10.1 points per 10 Gy, 95% CI: 3.7 to 16.5, &lt;i&gt;p&lt;/i&gt; = 0.002). Chemotherapy and prior surgery were not associated with any domain.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Long-term survivors of OPSCC reported favourable global QOL and little treatment regret after RT. However, dry mouth/sticky saliva remained a substantial burden, and more likely with higher contralateral parotid mean dose. These findings support ongoing contralateral parotid sparing and consideration of unilateral neck irradiation when oncologically appropriate, while recognising the cross-sectional cohort and need for rigorous prospective studies in this area.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 ","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Selected Immunophenotypic Markers in Childhood Non-Hodgkin's Lymphomas in Ghana: A Possible Tool for Effective Stratification of Patients and Assessment of Survival Outcomes","authors":"Samuel Asamoah Sakyi,&nbsp;Bernard Gyan,&nbsp;Ernest Adankwah,&nbsp;Ernest Kwasi Adjei,&nbsp;Vivian Paintsil,&nbsp;David Kwabena Adu,&nbsp;Manu Akwasi Owusu,&nbsp;Clement Binwatin Dagungong,&nbsp;Muniru Mohammed Tanko,&nbsp;Kervin Edinam Zogli,&nbsp;Alfred Effah,&nbsp;Samuel Kwame Sopuruchi Agomuo,&nbsp;Samuel Kwarteng,&nbsp;Beatrice Nyantakyiwaa,&nbsp;Edward Osei Gyimah,&nbsp;Harriet Yeboaa Diawuo,&nbsp;George Oduro Owusu,&nbsp;Ebenezer Senu,&nbsp;Oscar Simon Olympio Mensah,&nbsp;Stephen Opoku,&nbsp;Benjamin Amoani,&nbsp;Linda Ahenkorah Fondjo","doi":"10.1002/cnr2.70711","DOIUrl":"10.1002/cnr2.70711","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Non-Hodgkin lymphomas (NHL) represent a heterogeneous group of malignancies with varying molecular and immunophenotypic characteristics. In Ghana, NHL is the third most common childhood cancer, highlighting the need for precise diagnostic approaches to improve survival rates. The identification of immunophenotypic biomarkers expressed by both healthy and neoplastic cells of the immune systems has been shown to provide information on the diagnostic and prognostic characterization of tumors leading to personalized treatment of NHL. We evaluated the immunophenotypic profiles of pediatric NHL and their correlation with survival outcomes.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study aimed to evaluate the immunophenotypic characteristics of three subtypes of non-Hodgkin lymphoma (NHL) and their associated survival outcomes among children diagnosed at Komfo Anokye Teaching Hospital, Kumasi.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this retrospective study, 38 NHL patients were recruited from the Komfo Anokye Teaching Hospital from 2018 to 2022. Clinico-pathological characteristics and treatment outcome were obtained in patients' folders. Formalin fixed paraffin embedded tissues were histologically examined and immunohistochemistry performed using monoclonal antibodies targeting &lt;i&gt;CD3&lt;/i&gt;, &lt;i&gt;CD25&lt;/i&gt; and &lt;i&gt;BCL-2&lt;/i&gt;. The Kaplan–Meier method was used to obtain survival curves and compared by the log-rank test. Statistical analysis was performed using SPSS (version 26.0) and XLSTAT.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Females accounted for 55.3% of cases, with most patients being under 10 years. Within the first-year post-diagnosis, 30.6% of children died, and 27.8% abandoned treatment. &lt;i&gt;BCL-2&lt;/i&gt; was the most frequently expressed marker (55.3%), with co-expression observed across all lymphoma types and age groups. Survival analysis was performed on 21/38 participants with complete follow-up data. The median survival time was 22 months (95% CI: 3.96–40.11), with survival rates declining from 76% at 10 months to 20% at 40 months. Factors significantly associated with poor survival included &lt;i&gt;BCL-2&lt;/i&gt; expression (poorer survival) and extranodal spread (&lt;i&gt;p&lt;/i&gt; &lt; 0.05).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The survival rate for NHL patients in Ghana is very low. &lt;i&gt;BCL-2&lt;/i&gt; was the most expressed marker, significantly influencing survival outcomes. The extent of tumor spr","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13643208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}